|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song X, Zhao Z, Barber B, Gregory C,
Schutt D and Gao S: Characterizing medical care by disease phase in
metastatic colorectal cancer. Am J Manag Care. 17 (Suppl
5):SP20–SP25. 2011.PubMed/NCBI
|
|
3
|
Devesa H, Pereira L, Gonçalves A, Brito T,
Almeida T, Torres R and Midoes A: Axillary lymph node metastasis of
colon cancer-case report and literature review. Case Rep Clin Med.
12:669–673. 2014. View Article : Google Scholar
|
|
4
|
Kirstein MM, Lange A, Prenzler A, Manns
MP, Kubicka S and Vogel A: Targeted therapies in metastatic
colorectal cancer: A systematic review and assessment of currently
available data. Oncologist. 19:1156–1168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim DH, Sung B, Kang YJ, Hwang SY, Kim MJ,
Yoon JH, Im E and Kim ND: Sulforaphane inhibits hypoxia-induced
HIF-1α and VEGF expression and migration of human colon cancer
cells. Int J Oncol. 47:2226–2232. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ajith TA: Current insights and future
perspectives of hypoxia-inducible factor targeted therapy in
cancer. J Basic Clin Physiol Pharmacol. 30:11–18. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Semenza GL: HIF-1 mediates metabolic
responses to intratumoral hypoxia and oncogenic mutations. J Clin
Invest. 123:3664–3671. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nieves BJ, D'Amore PA and Bryan BA: The
function of vascular endothelial growth factor. Biofactors.
35:332–337. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iwasaki K, Yabushita H, Ueno T and
Wakatsuki A: Role of hypoxia-inducible factor-1α, carbonic
anhydrase-IX, glucose transporter-1 and vascular endothelial growth
factor associated with lymph node metastasis and recurrence in
patients with locally advanced cervical cancer. Oncol Lett.
10:1970–1978. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brahimi-Horn MC, Chiche J and Pouyssegur
J: Hypoxia and cancer. J Mol Med (Berl). 85:1301–1307. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cohen SA, Yu M, Baker K, Redman M, Wu C,
Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula
V, et al: The CpG island methylator phenotype is concordant between
primary colorectal carcinoma and matched distant metastases. Clin
Epigenetics. 9:462017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo KJ, Hu Y, Wen J and Fu JH: CyclinD1,
p53, E-cadherin, and VEGF discordant expression in paired regional
metastatic lymph nodes of esophageal squamous cell carcinoma: A
tissue array analysis. J Surg Oncol. 104:236–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Knosel T, Schluns K, Dietel M and Petersen
I: Chromosomal alterations in lung metastases of colorectal
carcinomas: Associations with tissue specific tumor dissemination.
Clin Exp Metastasis. 22:533–538. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Y, Jin M, Xu H, Shimin Z, He S, Wang L
and Zhang Y: Clinicopathologic significance of HIF-1α, CXCR4, and
VEGF expression in colon cancer. Clin Dev Immunol. 2010(pii):
5375312010.PubMed/NCBI
|
|
15
|
Qiu Y and Zhou H: Expression of HIF-1alpha
and VEGF in human laryngeal carcinoma and its relationship with
angiogenes. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.
28:389–393. 2014.(In Chinese). PubMed/NCBI
|
|
16
|
Matsuo Y, Ding Q, Desaki R, Maemura K,
Mataki Y, Shinchi H, Natsugoe S and Takao S: Hypoxia inducible
factor-1 alpha plays a pivotal role in hepatic metastasis of
pancreatic cancer: An immunohistochemical study. J Hepatobiliary
Pancreat Sci. 21:105–112. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schlingemann RO, Rietveld FJ, de Waal RM,
Bradley NJ, Skene AI, Davies AJ, Greaves MF, Denekamp J and Ruiter
DJ: Leukocyte antigen CD34 is expressed by a subset of cultured
endothelial cells and on endothelial abluminal microprocesses in
the tumor stroma. Lab Invest. 62:690–696. 1990.PubMed/NCBI
|
|
18
|
Hlatky L, Hahnfeldt P and Folkman J:
Clinical application of antiangiogenic therapy: microvessel
density, what it does and doesn't tell us. J Natl Cancer Inst.
94:883–893. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shimomura M, Hinoi T, Kuroda S, Adachi T,
Kawaguchi Y, Sasada T, Takakura Y, Egi H, Okajima M, Tashiro H, et
al: Overexpression of hypoxia inducible factor-1 alpha is an
independent risk factor for recurrence after curative resection of
colorectal liver metastases. Ann Surg Oncol. 20 (Suppl
3):S527–S536. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jensen NF, Smith DH, Nygard SB, Romer MU,
Nielsen KV and Brunner N: Predictive biomarkers with potential of
converting conventional chemotherapy to targeted therapy in
patients with metastatic colorectal cancer. Scand J Gastroenterol.
47:340–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ulivi P, Marisi G and Passardi A:
Relationship between hypoxia and response to antiangiogenic therapy
in metastatic colorectal cancer. Oncotarget. 7:46678–46691. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao D, Hou M, Guan YS, Jiang M, Yang Y and
Gou HF: Expression of HIF-1alpha and VEGF in colorectal cancer:
Association with clinical outcomes and prognostic implications. BMC
cancer. 9:4322009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Simiantonaki N, Taxeidis M, Jayasinghe C,
Kurzik-Dumke U and Kirkpatrick CJ: Hypoxia-inducible factor 1 alpha
expression increases during colorectal carcinogenesis and tumor
progression. BMC Cancer. 8:3202008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Berk V, Deniz K, Bozkurt O, Ozaslan E,
Karaca H, Inanc M, Duran AO and Ozkan M: Predictive significance of
VEGF and HIF-1α expression in patients with metastatic colorectal
cancer receiving chemotherapy combinations with bevacizumab. Asian
Pac J Cancer Prev. 16:6149–6154. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kurokawa T, Miyamoto M, Kato K, Cho Y,
Kawarada Y, Hida Y, Shinohara T, Itoh T, Okushiba S, Kondo S and
Katoh H: Overexpression of hypoxia-inducible-factor 1alpha
(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with
lymph node metastasis and pathologic stage. Br J Cancer.
89:1042–1047. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maxwell PH, Dachs GU, Gleadle JM, Nicholls
LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW and Ratcliffe PJ:
Hypoxia-inducible factor-1 modulates gene expression in solid
tumors and influences both angiogenesis and tumor growth. Proc Natl
Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ioannou M, Paraskeva E, Baxevanidou K,
Simos G, Papamichali R, Papacharalambous C, Samara M and Koukoulis
G: HIF-1α in colorectal carcinoma: Review of the literature. J
BUON. 20:680–689. 2015.PubMed/NCBI
|
|
29
|
Bar J, Herbst RS and Onn A: Targeted drug
delivery strategies to treat lung metastasis. Expert Opin Drug
Deliv. 6:1003–1016. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shim H, Lau SK, Devi S, Yoon Y, Cho HT and
Liang Z: Lower expression of CXCR4 in lymph node metastases than in
primary breast cancers: Potential regulation by ligand-dependent
degradation and HIF-1alpha. Biochem Biophys Res Commun.
346:252–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fraga CA, de Oliveira MV, de Oliveira ES,
Barros LO, Santos FB, Gomez RS, De-Paula AM and Guimarães AL: A
high HIF-1α expression genotype is associated with poor prognosis
of upper aerodigestive tract carcinoma patients. Oral Oncol.
48:130–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jilaveanu LB, Puligandla M, Weiss SA, Wang
XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran
A, Pins M, et al: Tumor microvessel density as a prognostic marker
in high-risk renal cell carcinoma patients treated on ECOG-ACRIN
E2805. Clin Cancer Res. 24:217–223. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peeters CF, Westphal JR, de Waal RM,
Ruiter DJ, Wobbes T and Ruers TJ: Vascular density in colorectal
liver metastases increases after removal of the primary tumor in
human cancer patients. Int J Cancer. 112:554–559. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo M, Mu Y, Yu D, Li J, Chen F, Wei B, Bi
S, Yu J and Liang F: Comparison of the expression of TGF-β1,
E-cadherin, N-cadherin, TP53, RB1CC1 and HIF-1α in oral squamous
cell carcinoma and lymph node metastases of humans and mice. Oncol
Lett. 15:1639–1645. 2018.PubMed/NCBI
|
|
35
|
Jeong HS, Jones D, Liao S, Wattson DA, Cui
CH, Duda DG, Willett CG, Jain RK and Padera TP: Investigation of
the lack of angiogenesis in the formation of lymph node metastases.
J Natl Cancer Inst. 107(pii): djv1552015.PubMed/NCBI
|
|
36
|
Roberts N, Kloos B, Cassella M,
Podgrabinska S, Persaud K, Wu Y, Pytowski B and Skobe M: Inhibition
of VEGFR-3 activation with the antagonistic antibody more potently
suppresses lymph node and distant metastases than inactivation of
VEGFR-2. Cancer Res. 66:2650–2657. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Willett CG, Duda DG, Ancukiewicz M, Shah
M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M,
et al: A safety and survival analysis of neoadjuvant bevacizumab
with standard chemoradiation in a phase I/II study compared with
standard chemoradiation in locally advanced rectal cancer.
Oncologist. 15:845–851. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stessels F, Van den Eynden G, Van der
Auwera I, Salgado R, V n den Heuvel E, Harris AL, Jackson DG,
Colpaert CG, van Marck EA, Dirix LY and Vermeulen PB: Breast
adenocarcinoma liver metastases, in contrast to colorectal cancer
liver metastases, display a non-angiogenic growth pattern that
preserves the stroma and lacks hypoxia. Br J Cancer. 90:1429–1436.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
van der Wal GE, Gouw AS, Kamps JA, Moorlag
HE, Bulthuis ML, Molema G and de Jong KP: Angiogenesis in
synchronous and metachronous colorectal liver metastases: The liver
as a permissive soil. Ann Surg. 255:86–94. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rajaganeshan R, Prasad R, Guillou PJ,
Scott N, Poston G and Jayne DG: Expression patterns of hypoxic
markers at the invasive margin of colorectal cancers and liver
metastases. Eur J Surg Oncol. 35:1286–1294. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Raluca BA, Cimpean AM, Cioca A, Cretu O,
Mederle O, Ciolofan A, Gaje P and Raica M: Endothelial cell
proliferation and vascular endothelial growth factor expression in
primary colorectal cancer and corresponding liver metastases. Asian
Pac J Cancer Prev. 6:4549–4553. 2015. View Article : Google Scholar
|
|
42
|
Sandhu J, Lavingia V and Fakih M: Systemic
treatment for metastatic colorectal cancer in the era of precision
medicine. J Surg Oncol. 119:564–582. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim YW, Ko YT, Kim NK, Chung HC, Min BS,
Lee KY, Park JP and Kim H: A comparative study of protein
expression in primary colorectal cancer and synchronous hepatic
metastases: The significance of matrix metalloproteinase-1
expression as a predictor of liver metastasis. Scand J
Gastroenterol. 45:217–225. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nakamoto RH, Uetake H, Iida S, Kolev YV,
Soumaoro LT, Takagi Y, Yasuno M and Sugihara K: Correlations
between cyclooxygenase-2 expression and angiogenic factors in
primary tumors and liver metastases in colorectal cancer. Jpn J
Clin Oncol. 37:679–685. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kobayashi H, Sugihara K, Uetake H, Higuchi
T, Yasuno M, Enomoto M, Kuramochi H, Lenz HJ, Danenberg KD and
Danenberg PV: Messenger RNA expression of vascular endothelial
growth factor and its receptors in primary colorectal cancer and
corresponding liver metastasis. Ann Surg Oncol. 15:1232–1238. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Klein CA: Parallel progression of primary
tumors and metastases. Nat Rev Cancer. 9:302–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
